Toothbrushing initiative to begin in bid to improve children's oral health
The programme, aimed at children aged between three and five, will be rolled out in early years settings and primary schools across the North West of England, the government announced.
The initiative, which is part of the government's Plan for Change, will receive £2.4 million in funding to help children in the most deprived areas develop positive brushing habits.
The programme will be launched in collaboration with Colgate-Palmolive, who will provide free toothbrushes, toothpaste, and educational materials to support good oral hygiene at home.
The government said this is a 'crucial' step in addressing the children's oral health crisis, as tooth decay is the most common reason for hospital admissions among children aged five to nine.
Data reveals that 'more than one in four children aged five in the North West have experienced tooth decay'.
The programme aims to tackle these levels of poor health by ensuring children receive the support they need to learn positive habits and prevent tooth decay, thereby avoiding related illnesses and poor health later in life.
Health Minister Stephen Kinnock said: "It is shocking that a third of five-year-olds in the most deprived areas have experience of tooth decay - something we know can have a lifelong impact on their health.
"It's why we're delivering supervised toothbrushing to young children and families who are most in need of support as part of our wider plans to revive the oral health of the nation."
The government has also agreed on a partnership with Colgate-Palmolive, which has committed to donating over 23 million toothbrushes and toothpastes over the next five years.
The resources will reach up to 600,000 children each year and provide families with the support they need to ensure positive behaviours continue at home and over the school holidays.
Colgate-Palmolive's chairman, president and CEO, Noel Wallace, said: "At Colgate-Palmolive, we believe every child deserves the chance to have a healthier smile and brighter future.
"We're thrilled that Colgate and our team in the UK have been chosen to partner with the government to help improve children's oral health across the country.
"In the UK, we've been running Colgate Bright Smiles, Bright Futures™ since 2014 and are extremely proud to have reached over 18 million children across the nation with oral health education and donations of essential health and hygiene products."
The scheme will be rolled out in collaboration with the Department for Education and follows the latest measures to make government-funded childcare 'more affordable and accessible to the most disadvantaged families'.
Early years providers such as primary schools and nurseries are required to promote good oral health among attending children, and supervised toothbrushing is a way of achieving that aim.
Jason Wong, chief dental officer for England, said: "Tooth brushing twice daily with a fluoride toothpaste remains one of the best defences against tooth decay and a long list of preventable oral health issues.
"This is why we're thrilled that the government is working with the NHS to expand access to pivotal supervised toothbrushing programmes in schools.
'Having strong healthy teeth can have a hugely positive impact on a child's life.
"If you're concerned about your child's oral health, you can find helpful guidance on the NHS website or through your local authority – and as a reminder to parents, all children have free dental care available through the NHS.'
The rollout is expected to save the NHS millions of pounds that would otherwise be spent on treating dental disease in children, including preventing hospital admissions that cost the NHS around £1,600 per person.
Anna Gardiner, deputy director of health & wellbeing at the National Children's Bureau, said: "Despite improvements over the past 20 years, too many young children in England start school with tooth decay.
"Poor oral health can have lasting impacts on their health, wellbeing, and attainment, and a significant risk factor is not getting into the habit of brushing teeth twice per day with fluoride toothpaste.
"So, we welcome the Government's plans to introduce a supervised brushing programme in early years settings, and we look forward to seeing its impact, particularly for those growing up in deprived areas who disproportionately suffer from poor oral health."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
Navitus Health Solutions Earns 2025-2026 Great Place To Work Certification™
MADISON, Wis.--(BUSINESS WIRE)-- Navitus Health Solutions announced today it has been Certified™ by Great Place To Work ®. The prestigious award is based entirely on what current associates say about their experience working at the company. This year, 85% of associates said it's a great place to work – more than 25 points higher than the average U.S. company. Associates recognized the company's culture as welcoming and engaging, with remarkable opportunities for professional growth. 'Navitus Health Solutions strives to be a preferred employer. We recruit and retain top talent, incorporate equitable representation at every level of the organization, and implement effective learning and development opportunities,' said David Fields, President and CEO, Navitus Health Solutions. 'We're proud to become Great Place To Work-Certified™, a recognition that reflects our ongoing commitment to cultivating a culture rooted in purpose, passion and putting people first.' Great Place To Work ® is the global authority on workplace culture, associate experience, and leadership behaviors proven to deliver market-leading revenue, associate retention and increased innovation. "Great Place To Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall associate experience," says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of associates regarding their company culture. 'By successfully earning this recognition, it is evident that Navitus Health Solutions stands out as one of the top companies to work for, providing a great workplace environment for its associates." For more than 20 years, Navitus Health Solutions has been an innovator in removing cost from the drug supply chain, first as a 100% transparent, pass-through PBM and then through its specialty pharmacy and medical specialty management capabilities. With the ongoing need for greater accessibility and medication affordability, the company continues to advance its mission on behalf of its various stakeholders. As an employer, Navitus Health Solutions is committed to creating an environment where associates can advance their careers and develop into future leaders within the company. The culture reflects an unwavering commitment to innovation, collaboration and doing what's right to make a positive impact on the lives of its members and in the communities it serves. 'Every associate understands how their work contributes to something larger than themselves. This clarity of mission creates alignment, engagement and a deep sense of meaning,' said David Simmons, Chief People & Culture Officer. 'We continue to focus on and fuel a work environment focused on community, recognition, communication, mentorship and continued career growth.' To learn more about working at Navitus Health Solutions, please visit: About Navitus Health Solutions Navitus Health Solutions is a pioneering pharmacy solutions provider that first launched a transparent pharmacy benefit manager (PBM) to pass through 100% of negotiated drug rebates and discounts to health plans and plan sponsors. The Navitus PBM is an alternative to traditional PBMs which divert rebates and discounts for profit. It leads the way in driving meaningful cost savings to help make medications more affordable. More than 20 years after its founding, the Navitus Health Solutions organization delivers a range of services through portfolio brands including Navitus, Lumicera and Archimedes. Owned by SSM Health and Costco Wholesale Corporation, the company serves over 18 million members across 800 clients, including public and private sector employers, unions, health plans and health systems. For more information, please visit


Business Wire
2 hours ago
- Business Wire
Concord Technologies Introduces Direct Secure Messaging Within its Concord Connect™ Platform to Transform Healthcare Data Exchange
SEATTLE--(BUSINESS WIRE)--Concord Technologies ('Concord'), a leader in Secure Document Exchange, Intelligent Document Processing, and Interoperability solutions, today announced the upcoming launch of Direct Secure Messaging (DSM) within its Concord Connect™ platform, available Fall 2025. This enhancement marks a significant step forward in enabling healthcare organizations to modernize how patient information is received, processed, and integrated across systems. Healthcare teams face persistent challenges in managing patient data during transitions of care and care coordination. Information often arrives from disparate systems and in both structured and unstructured formats, making timely, secure, and compliant data exchange difficult. DSM is a secure transport protocol that supports the exchange of a wide range of healthcare-related information. It is built on the widely adopted Direct Standard® and enables the secure, encrypted exchange of clinical information between trusted healthcare entities. With the addition of DSM, Concord Connect™ will support secure delivery of clinical records via a DSM address alongside Digital Fax. Using Concord's Practical AI™, these incoming documents are then indexed into appropriate queues where key pieces of patient data—whether structured or unstructured—are extracted and analyzed for intelligent workflow automation and insertion into systems of record. This process, known as Straight-Through Processing, simplifies intake workflows, accelerates integration with downstream technologies, and minimizes delays in the triage and processing of critical patient information. 'At this year's DirectTrust® Annual Conference, it was exciting to see our vision for secure, interoperable data exchange validated,' noted Chris Larkin, Chief Technology Officer of Concord. 'Concord's ability to intelligently receive and process both structured and unstructured data addresses one of healthcare's most persistent challenges: fragmented intake workflows. By integrating multiple modalities like Digital Fax and Direct Secure Messaging into a single platform, we're enabling providers to triage and route patient information faster than ever before. The enthusiastic response from industry leaders confirms we're solving real problems—and we're just getting started." "Our vision for Straight-Through Processing is grounded in addressing the critical challenges faced by healthcare organizations,' said William Cavanaugh, Chief Executive Officer of Concord. 'Concord Connect is a powerful example of that vision in action—bringing together structured and unstructured data into a single, intelligent workflow. By streamlining the sharing and processing of patient data, and enabling Straight-Through Processing, we're helping providers accelerate care delivery and reduce administrative burden, all while maintaining the highest standards of security and compliance." About Concord Technologies Concord Technologies is a leading provider of Secure Document Exchange, Intelligent Document Processing, and Interoperability solutions to healthcare providers, payers, and other highly regulated businesses. For more than 20 years, billions of sensitive records containing valuable patient information have been reliably, accurately, and securely sent and received across Concord's digital health network, and today, the company processes more than 4 billion pages of protected data each year. The company is also recognized for its best-in-class development of new artificial intelligence technologies, including Concord's Practical AI™ approach to solving the most pervasive administrative challenges in the healthcare industry and for its industry-leading applications that help its customers grow and manage their business.


Business Wire
3 hours ago
- Business Wire
Techcyte and Modella AI Announce a Research Collaboration with Modella AI's State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform
OREM, Utah--(BUSINESS WIRE)-- Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion ™ (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings together Modella AI's groundbreaking research-use only AI co-pilot for pathologists, PathChat ™, with Techcyte's integrated, cloud-based digital pathology platform—supporting the advancement of workflow efficiency and expanding access to advanced AI-powered pathology tools for research. 'Modella AI's commitment to innovation, including agentic AI, and Techcyte's unified pathology platform create a powerful research combination,' said Matt Smith, Chief Strategy Officer at Techcyte. Modella AI is a biomedical artificial intelligence company focused on improving pathology through generative and agentic AI. Its flagship research product, PathChat, enables intelligent interactions with digital slides—offering capabilities such as report summarization, image interpretation, and contextual question answering. An advanced research-use only version of the tool, PathChat DX, has been granted U.S. Food and Drug Administration Breakthrough Device Designation, reflecting the device's potential to provide a more effective diagnosis of a life-threatening or irreversibly debilitating condition. While this designation recognizes the potential of the technology, any use of PathChat within the Techcyte Fusion platform remains for research use only and is not intended for clinical diagnostic purposes. 'Modella AI's commitment to innovation, including agentic AI, and Techcyte's unified pathology platform create a powerful research combination,' said Matt Smith, Chief Strategy Officer at Techcyte. 'Together, our goal is delivering practical AI that pathologists can trust and that seamlessly integrates into their digital workflows.' 'We're excited to partner with Techcyte to bring our pathology-native AI to a broader research audience,' said Jill Stefanelli, President, Cofounder, and Chief Executive Officer at Modella AI. 'Integrating PathChat into the Fusion research platform supports the exploration of AI-assisted workflows in pathology and reflects our shared commitment to advancing digital innovation in the lab.' The integration of PathChat into Techcyte Fusion represents a significant step forward in operationalizing next-generation AI. As pathology workloads increase and case complexity grows, this collaboration represents an important step toward exploring AI capabilities in digital pathology research settings—all within the familiar Techcyte platform. For more information about the Techcyte Fusion Partner Program, visit About Techcyte Techcyte is aiming to transform the practice of pathology through a unified, AI-powered digital platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab. By partnering with leading laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers, we deliver a unified digital pathology platform to labs and clinics around the world, furthering our mission to positively impact the health of humans, animals, and the environment. Visit for more information. Techcyte's anatomic and clinical pathology platform is for Research Use Only in the United States. About Modella Modella AI ( is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. By combining expertise in artificial intelligence and pathology, Modella AI aims to deliver innovative solutions that empower clinicians, improve patient outcomes, and transform medical workflows. Disclaimer: PathChat ™, PathChat ™ DX and the Techcyte Fusion ™ platform are research-use only devices and are not commercially available in the United States (as they are not FDA cleared or approved). The Techcyte Fusion platform is commercially available in Europe for diagnostic use. The FDA Breakthrough Device Designation for PathChat DX does not imply FDA clearance or approval. This press release contains forward-looking statements based on current assumptions and forecasts. Modella AI and Techcyte assume no obligation to update these statements to reflect future events or developments.